Krsnaa Diagnostics Limited Latest Updates

$KRSNAA FY26 Financial Summary For the full financial year 2025-26, the company posted a consolidated revenue from operations of ₹772.77 crore (+7.75% YoY). Backed by solid execution, its annual consolidated net profit rose by 30.7% to ₹101.43 crore, hitting the highest reported profit after tax in the company's history since listing. Rapid Retail Diagnostics Scaling The group's specialized retail vertical (Krsnaa Retail) turned into an independent growth pillar, delivering an 8x vertical surge in revenue to hit ₹60 crore for the fiscal year. The asset-light retail network scaled up rapidly to include more than 3,500 collection touchpoints distributed across 5 core states. Dividend Recommendation Aligning with its formal board approvals filed on May 25, 2026, the company recommended a final dividend of ₹2.00 per equity share (representing 40% of the ₹5 face value) for FY25-26. This distribution remains subject to final shareholder ratification at the company's upcoming Annual General Meeting. Strategic Network Reach The company closed out the fiscal year servicing over 20 million individual patients and processing a total of 59 million tests. Its public-private partnership (PPP) network and private infrastructure expanded to comprise 190 CT/MRI radiology centers, 147 core pathology processing labs, and an expansive pool of over 4,700 processing touchpoints. Q4 FY26 Explosive Profit Surge During the final quarter ended March 31, 2026, operational revenue grew 3.5% year-on-year to ₹192.60 crore. Driven by optimized capacity utilization across regional diagnostic hubs and an embedded fair valuation gain of ₹22.17 crore from its strategic Apulki Healthcare investment, the company’s Q4 net profit doubled (+101.75% YoY) to ₹41.72 crore.